Wells Fargo & Company Kintara Therapeutics, Inc. Transaction History

Wells Fargo & Company

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.14 - $6.8 $6 - $306	45 Added 11.54%	435 $0
Q2 2022 Aug 12, 2022	BUY	$0.14 - $0.5 $16 - $60	121 Added 44.98%	390 $0
Q1 2022 May 16, 2022	BUY	$0.31 - $0.55 $10 - $18	33 Added 13.98%	269 $0
Q4 2021 Feb 14, 2022	BUY	$0.51 - $1.04 $22 - $46	45 Added 23.56%	236 $0
Q3 2021 Nov 15, 2021	SELL	$0.82 - $2.3 $31 - $87	-38 Reduced 16.59%	191 $0
Q2 2021 Aug 16, 2021	BUY	$1.26 - $2.4 $12 - $24	10 Added 4.57%	229 $0
Q1 2021 May 13, 2021	BUY	$1.32 - $2.74 $92 - $191	70 Added 46.98%	219 $0
Q4 2020 Feb 09, 2021	BUY	$1.26 - $1.72 $105 - $144	84 Added 129.23%	149 $0
Q3 2020 Nov 05, 2020	BUY	$0.63 - $1.7 $40 - $110	65 New	65 $0

Ticker KTRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,807,296
Market Cap $17.8M
Description
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme,...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.